2-hydroxy-dATP diphosphatase (EC184.108.40.206, also known as oxidized purine nucleoside triphosphatase, or (2'-deoxy) ribonucleoside 5'-triphosphate pyrophosphohydrolase, or Nudix hydrolase 1 (NUDT1), or MutT homolog 1 (MTH1), or 7,8-dihydro-8-oxoguanine triphosphatase) is an enzyme that in humans is encoded by the NUDT1gene. During DNA repair, the enzyme hydrolyses oxidized purines and prevents their addition onto the DNA chain. As such it has important role in aging and cancer development.
Example hydrolysis of oxidized nucleotide catalyzed by MTH1
MutT enzymes in non-human organisms often have substrate specificity for certain types of oxidized nucleotides, such as that of E. coli, which is specific to 8-oxoguanine nucleotides. Human MTH1, however, has substrate specificity for a much broader range of oxidatively damaged nucleotides. The mechanism of hMTH1's broad specificity for these oxidized nucleotides is derived from their recognition in the enzyme's substrate binding pocket due to an exchange of protonation state between two nearby aspartate residues.
Examples of the protonation state exchange between MTH1 residues Asp-119 and Asp-120 that allows the enzyme to recognize oxidized nucleotides.
The encoded protein is localized mainly in the cytoplasm, with some in the mitochondria, suggesting that it is involved in the sanitization of nucleotide pools both for nuclear and mitochondrial genomes. In plants, MTH1 has also been shown to enhance resistance to heat- and paraquat-induced oxidative stress, resulting in fewer dead cells and less accumulation of hydrogen peroxide.
Several alternatively spliced transcript variants, some of which encode distinct isoforms, have been identified. Additional variants have been observed, but their full-length natures have not been determined. A single-nucleotide polymorphism that results in the production of an additional, longer isoform has been described.
A mouse model has been studied that over-expresses hMTH1-Tg (NUDT1). The hMTH1-Tg mice express high levels of the hMTH1 hydrolase that degrades 8-oxodGTP and 8-oxoGTP and therefore excludes 8-oxoguanine from DNA and RNA. The steady state levels of 8-oxoguanine in DNA of several organs including the brain are significantly reduced in hMTH1-Tg over-expressing mice. Conversely, MTH1-null mice exhibit a significantly higher level of 8-oxo-dGTP accumulation than that of the wild type. Over-expression of hMTH1 prevents the age-dependent accumulation of DNA 8-oxoguanine that occurs in wild-type mice. The lower levels of oxidized guanines are associated with greater longevity. The hMTH1-Tg animals have a significantly longer lifespan than their wild-type littermates. These findings provide a link between ageing and oxidative DNA damage (see DNA damage theory of aging).
Studies have suggested that this enzyme plays a role in both preventing the formation of cancer cells and the proliferation of cancer cells. This makes it a topic of interest in cancer research, both as a potential method for healthy cells to prevent cancer and a weakness to target within existing cancer cells.
Eliminating the MTH1 gene in mice results in over three times more mice developing tumors compared to a control group. The enzyme's much-studied ability to sanitize a cell's nucleotide pool prevents it from developing mutations, including cancerous ones. Specifically, another study found that MTH1 inhibition in cancer cells leads to incorporation of 8-oxo-dGTP and other oxidatively damaged nucleotides into the cell's DNA, damaging it and causing cell death. However, cancer cells have also been shown to benefit from use of MTH1. Cells from malignant breast tumors exhibit extreme MTH1 expression compared to other human cells. Because a cancer cell divides much more rapidly than a normal human cell, it is far more in need of an enzyme like MTH1 that prevents fatal mutations during replication. This property of cancer cells could allow for monitoring of cancer treatment efficacy by measuring MTH1 expression. Development of suitable probes for this purpose is currently underway.
Disagreement exists concerning MTH1's functionality relative to prevention of DNA damage and cancer. Subsequent studies have had difficulty reproducing previously reported cytotoxic or antiproliferation effects of MTH1 inhibition on cancer cells, even calling into question whether MTH1 truly does serve to remove oxidatively damaged nucleotides from a cell's nucleotide pool. One study of newly discovered MTH1 inhibitors suggests that these anticancer properties exhibited by the older MTH1 inhibitors may be due to off-target cytotoxic effects. After revisiting the experiment, the original authors of this claim found that while the original MTH1 inhibitors in question lead to damaged nucleotides being incorporated into DNA, they demonstrate the others that do not induce toxicity fail to introduce the DNA lesion. Research into this topic is ongoing.
As a drug target
MTH1 is a potential drug target to treat cancer, however there are conflicting results regarding the cytotoxicity of MTH1 inhibitors toward cancer cells.
Karonudib, an MTH1 inhibitor, is currently being evaluated a phase I clinical trial for safety and tolerability.
A potent and selective MTH1 inhibitor AZ13792138 has been developed by AstraZeneca has been made available as a chemical probe to academic researchers. However AstraZeneca has found that neither AZ13792138 nor genetic knockdown of MTH1 displays any significant cytotoxicity to cancer cells.
^Ponnambalam S, Jackson AP, LeBeau MM, Pravtcheva D, Ruddle FH, Alibert C, Parham P (December 1994). "Chromosomal location and some structural features of human clathrin light-chain genes (CLTA and CLTB)". Genomics. 24 (3): 440–4. doi:10.1006/geno.1994.1650. PMID7713494.
^Sakumi K, Furuichi M, Tsuzuki T, Kakuma T, Kawabata S, Maki H, Sekiguchi M (November 1993). "Cloning and expression of cDNA for a human enzyme that hydrolyzes 8-oxo-dGTP, a mutagenic substrate for DNA synthesis". The Journal of Biological Chemistry. 268 (31): 23524–30. PMID8226881.
^Gad H, Koolmeister T, Jemth AS, Eshtad S, Jacques SA, Ström CE, et al. (April 2014). "MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool". Nature. 508 (7495): 215–21. doi:10.1038/nature13181. PMID24695224.
^Coskun E, Jaruga P, Jemth AS, Loseva O, Scanlan LD, Tona A, Lowenthal MS, Helleday T, Dizdaroglu M (September 2015). "Addiction to MTH1 protein results in intense expression in human breast cancer tissue as measured by liquid chromatography-isotope-dilution tandem mass spectrometry". DNA Repair. 33: 101–10. doi:10.1016/j.dnarep.2015.05.008. PMID26202347.
^Samaranayake GJ, Troccoli CI, Huynh MQ, Win A, Ji D, Kool ET, Rai P (July 2017). "Towards a better understanding of MTH1 as a therapeutic target in RAS-driven cancer [abstract]". Cancer Res. 77 (13): 5473. doi:10.1158/1538-7445.AM2017-5473.
^Petrocchi A, Leo E, Reyna NJ, Hamilton MM, Shi X, Parker CA, Mseeh F, Bardenhagen JP, Leonard P, Cross JB, Huang S, Jiang Y, Cardozo M, Draetta G, Marszalek JR, Toniatti C, Jones P, Lewis RT (March 2016). "Identification of potent and selective MTH1 inhibitors". Bioorganic & Medicinal Chemistry Letters. 26 (6): 1503–7. doi:10.1016/j.bmcl.2016.02.026. PMID26898335.
Furuichi M, Yoshida MC, Oda H, Tajiri T, Nakabeppu Y, Tsuzuki T, Sekiguchi M (December 1994). "Genomic structure and chromosome location of the human mutT homologue gene MTH1 encoding 8-oxo-dGTPase for prevention of A:T to C:G transversion". Genomics. 24 (3): 485–90. doi:10.1006/geno.1994.1657. PMID7713500.
Topp H, Armbrust S, Lengger C, Schöch G, Davies J, Stichler W, Manz F, Fusch C (June 2002). "Renal excretion of 8-oxo-7,8-dihydro-2(')-deoxyguanosine: degradation rates of RNA and metabolic rate in humans". Archives of Biochemistry and Biophysics. 402 (1): 31–7. doi:10.1016/S0003-9861(02)00034-6. PMID12051680.
Takahashi M, Maraboeuf F, Sakai Y, Yakushiji H, Mishima M, Shirakawa M, Iwai S, Hayakawa H, Sekiguchi M, Nakabeppu Y (May 2002). "Role of tryptophan residues in the recognition of mutagenic oxidized nucleotides by human antimutator MTH1 protein". Journal of Molecular Biology. 319 (1): 129–39. doi:10.1016/S0022-2836(02)00163-8. PMID12051941.
Liu Z, Wang LE, Strom SS, Spitz MR, Babaian RJ, DiGiovanni J, Wei Q (March 2003). "Overexpression of hMTH in peripheral lymphocytes and risk of prostate cancer: a case-control analysis". Molecular Carcinogenesis. 36 (3): 123–9. doi:10.1002/mc.10108. PMID12619034.
Bialkowski K, Kasprzak KS (September 2003). "Inhibition of 8-oxo-2'-deoxyguanosine 5'-triphosphate pyrophosphohydrolase (8-oxo-dGTPase) activity of the antimutagenic human MTH1 protein by nucleoside 5'-diphosphates". Free Radical Biology & Medicine. 35 (6): 595–602. doi:10.1016/S0891-5849(03)00362-9. PMID12957652.
Kamiya H, Yakushiji H, Dugué L, Tanimoto M, Pochet S, Nakabeppu Y, Harashima H (February 2004). "Probing the substrate recognition mechanism of the human MTH1 protein by nucleotide analogs". Journal of Molecular Biology. 336 (4): 843–50. doi:10.1016/j.jmb.2003.12.060. PMID15095864.